INTRODUCTION
============

After entry into a target host cell, retroviruses carry out reverse transcription for the synthesis of double-stranded DNA from their RNA genome in a complex derived from the viral core. Subsequently, the newly synthesized viral DNA remains associated with viral and cellular proteins and forms a high-ordered nucleoprotein complex called the preintegration complex (PIC). The PIC guides nuclear entry and the subsequent integration process of the viral DNA genome ([@B84]). The viral DNA that is integrated into chromosomal DNA, termed the provirus, acts as a template for the efficient transcription of viral RNA and ensures the equal segregation of genetic material to daughter cells upon division. Once established, proviruses cannot be distinguished or excised from the cellular genomic DNA of infected cells. Therefore, integration occupies an important place not only in viral replication but also in the treatment of retroviral infectious diseases ([@B49]).

The viral enzyme catalyzing the integration is integrase (IN). As shall be shown, the chemical mechanism of the integration reaction has been elucidated by biochemical studies using oligonucleotide DNA substrates and purified IN protein produced by the *Escherichia coli* system ([@B9]; [@B20]; [@B43]; [@B75]). These studies indicate that IN alone can carry out the DNA breakage and joining reactions during integration ([@B25]; [@B88]). However, the reaction by recombinant IN lacks the full fidelity of DNA integration observed in virus-infected cells. In contrast, PICs extracted from infected cells efficiently insert both viral DNA ends into a target DNA in a concerted manner *in vitro*, a hallmark of the integration reaction *in vivo*, indicating that the PIC harbors additional factors essential for the authentic integration in cells ([@B33]; [@B4]; [@B7]; [@B30]; [@B88]). Indeed, a number of cellular proteins have since been identified as co-factors of retroviral IN and PICs ([@B88]; [@B2]).

As seen with the integration step, retroviruses need to hijack host biological processes to execute their efficient replication in the cell ([@B35]). Under the selection pressure of such viral virulence mechanisms, the host organism has itself evolved cellular antiviral defense strategies called intrinsic immunity, which block virus replication at the post-entry, post-integration, and virion release steps ([@B98]), and in addition to well-studied antiviral cellular proteins such as APOBEC and TRIM family proteins, intense efforts have been dedicating to identify novel inhibitory factors against retroviruses ([@B53]; [@B89]). Intriguingly, new cellular inhibitory factors for retroviral integration are also beginning to attract attention. Although viruses may be still capable of surmounting the host defense system, further understanding of the host's inhibitory machineries could potentially translate into new treatments for retroviral infectious diseases. Here, we focus on the recent findings that illustrate the involvement and molecular mechanisms of potential restriction factors for retroviral integration.

BIOCHEMICAL FEATURES OF THE INTEGRATION REACTION
================================================

Retroviral IN is expressed and incorporated into virions as the C-terminal part of the Gag-Pol polyprotein precursor during the late phase of retroviral infection. IN comprises three structurally and functionally distinct domains, termed the N-terminal domain (NTD), the catalytic core domain (CCD), and the C-terminal domain (CTD; **Figure [1A](#F1){ref-type="fig"}**; [@B49]). The NTD of IN is relatively well conserved amongst retroviruses especially with the respect to a motif consisting of two histidines and two cysteines (HHCC motif). This HHCC motif makes up the zinc-binding site with an overall helix-turn-helix fold commonly found in IN of all retroviruses and retrotransposons ([@B19]). Further studies utilizing mutants containing amino acid mutations in the HHCC motif also elucidated the importance of the NTD in the key steps of integration as well as its involvement in the multimerization of IN ([@B107]; [@B48]; [@B19]). The CCD is composed of a mixture of α-helices and β-sheets folds that bring a triad of critical acidic residues called the DDE motif into close proximity ([@B49]). Crystal structure studies of HIV-1 and avian sarcoma virus (ASV) IN have shown this motif to be important for the binding of divalent metal cations such as Mg^2+^([@B19]). Additionally, the CCD was also shown to possess viral DNA recognition and binding ability ([@B49]). Compared to the NTD and CCD of IN, the CTD displays the greatest degree of variation across the retrovirus family. Despite this, studies on the CTD region of HIV-1 have revealed that it has strong DNA-binding activity and also potentially has multimerization capabilities ([@B96]; [@B27]; [@B56]; [@B34]).

![**Retroviral DNA integration.** **(A)** As an example of retroviral INs, domain organization of HIV-1 IN is illustrated. IN is composed of three domains: N-terminal domain (NTD), catalytic core domain (CCD), and C-terminal domain (CTD). A triad of aspartic (D) and glutamic acid (E) residues termed the DDE motif is found in the CCD, which is highly conserved amongst retroviral INs. Binding of divalent ions such as Mg^2+^ to the DDE motif domain plays a key role in integration reaction. The NTD contains a well-conserved motif comprising of two histidine (H) and two cysteine (C) residues (HHCC motif) that coordinates Zn^2+^ binding. In contrast to the NTD and CCD, the CTD is the least conserved domain, although tryptophan (W) is conserved among the retroviral INs. This domain exhibits non-specific DNA-binding activity *in vitro*. **(B)** Retroviral integration is initiated by IN's recognition of both ends of viral DNA and subsequent removal of two (or three) nucleotides from each of the 3′ ends (3′ processing). The target DNA (i.e., chromosomal DNA) captured by IN is cleaved in a staggered fashion via the exposed hydroxy (OH) groups on the viral DNA ends, and the 3′ end of the viral DNA and the 5′ end of the target DNA is simultaneously linked (strand transfer). The 3′ processing and strand transfer steps are reproducible in vitro using recombinant IN, indicating that IN alone suffices to catalyze these steps. However, in infected cells, excision of the mispaired 5′ viral DNA ends and filling in the single-strand gaps are carried out by yet-to-be identified cellular enzymes.](fmicb-03-00227-g001){#F1}

The retrovirus-mediated integration reaction consists of three biochemically distinct steps (**Figure [1B](#F1){ref-type="fig"}**; [@B19]). In the first step, IN specifically recognizes the viral attachment (*att*) sites on the 5′ and 3′ long terminal repeats (LTRs) of newly synthesized viral DNA ends. This interaction between IN and DNA allows for the 3′ processing of viral DNA, where water serves as the nucleophile for the cleavage of viral DNA. In this 3′ processing step, most retroviral IN such as HIV-1 IN catalyze the removal of two nucleotides adjacent to the highly conserved CA dinucleotide from the 3′ end of LTR regions. This chemically activates the viral DNA through the formation of 3′ hydroxyl radicals at the terminal ends of viral DNA, allowing it to participate in the next reaction.

The second step of integration involves the insertion of 3′ processed, activated viral DNA strand into the target DNA through a single transesterification reaction, which is called the strand transfer step ([@B28]). IN brings the viral DNA ends into close proximity with the target DNA allowing a nucleophilic attack by the 3′ hydroxyl radical on the target DNA. Subsequently, IN ligates both the 3′ hydroxyl radical terminal of the viral DNA to the 5′ phosphoryl ends of the target DNA and establishes new phosphodiester bond between them. This forms intermediate DNA products with unrepaired gaps between the non-ligated 5′ ends of viral DNA as well as the 3′ ends of target DNA. Additionally, the unrepaired gaps result in the short duplication of target DNA sequences flanking both strand ends, followed by the formation of imperfect inverted repeats upon the sealing of the nick. The length of this inverted repeat sequences can vary from 4 to 6 base pairs (bp) and is highly characteristic of the retrovirus species from which the IN protein is derived. It should be noted that the 3′ processing and strand transfer steps have been shown to be catalyzed by IN proteins through various *in vitro* studies conducted with *E. coli*-expressed IN and DNA substrates harboring viral LTR sequence ([@B88]).

Lastly, after the ligation reaction, the gaps in the intermediate DNA products are repaired to yield fully functional integrated proviruses (gag repair step). The previous step generates an intermediate product in which viral DNA is joined to the target DNA solely by the 3′ ends of both strands. As such, DNA repair is needed to seal the nick between the 5′ end of viral DNA and the 3′ end of the target DNA to complete the provirus formation. Unlike the earlier steps which are catalyzed by IN, this step is probably mediated by some cellular enzymes involved in a variety of DNA repair pathways including the non-homologous end joining (NHEJ) repair pathway. However, whether or not the NHEJ machinery is involved is controversial, and identification of the specific enzymes conducting this gap repair step is anticipated in future studies ([@B88]; [@B77]; [@B103]).

HOST PROTEINS ASSOCIATED WITH THE RETROVIRAL INTEGRATION COMPLEX
================================================================

The PIC, the key nucleoprotein complex responsible for the integration, is formed in the cytoplasm following the reverse transcription of viral DNA from the RNA genome (**Figure [2](#F2){ref-type="fig"}**). Although the full composition of this nucleoprotein complex has yet to be determined, most of the viral protein components of the PIC are thought to be derived from the core of the infecting virion, which includes not only IN but also reverse transcriptase (RT), matrix (MA), capsid (CA), and some HIV-1 accessory proteins ([@B84]). With respect to the cellular components of the PIC, significant efforts have been made to identify them through surveys of IN-interacting proteins using yeast two-hybrid screenings and/or co-immunoprecipitation analysis (**Figure [2](#F2){ref-type="fig"}**; [@B88]).

![**Possible roles of IN- and PIC-associated cellular proteins in retrovirus replication.** After penetrating the cell membrane, the viral nucleoprotein core containing genomic RNA is released into the cytoplasm, after which reverse transcription of the viral RNA takes place. The synthesis of full-length viral DNA produces the PIC, in which cellular as well as viral proteins including IN are associated. 3′ processing of the viral DNA by IN occurs in the cytoplasmic PIC. Once the PIC reaches the nuclear periphery it must gain entry into the nucleus for integration. Some retroviruses seem to take advantage of nuclear-envelope disassembly during cell division to access chromosomal DNA, whereas the PICs of lentiviruses, including HIV-1, are believed to be capable of crossing the intact nuclear-envelope during interphase. In the nucleus, the PIC gains access to chromosomal DNA and mediates viral DNA integration to produce a provirus, which is acted upon by viral and/or cellular transcription factors to express viral RNAs. To date, a number of host proteins have been reported to interact with the retroviral IN and PIC (representative proteins are listed on the right). Many of them are likely to assist in the integration step, and some other cofactors appear to have functional roles in other steps including reverse transcription, nuclear entry, gene expression, and virion production during virus infection. In addition, recent studies demonstrate that several cellular interactors of IN may negatively regulate retrovirus replication (highlighted in red).](fmicb-03-00227-g002){#F2}

Integrase interactor 1 (INI1), also known as hSNF5, was the first binding partner of HIV-1 IN identified by yeast two-hybrid assay ([@B42]). This nuclear protein is the human homolog of the yeast SNF5 protein, a transcription activator and part of the SWI/SNF complex in mammalian systems ([@B93]). Interaction with the HIV-1 IN requires a direct imperfect repeat region of INI1 termed Rpt1 ([@B104]). The function of INI1 in HIV-1 integration was demonstrated in an *in vitro* integration assay where it stimulated the strand transfer activity of recombinant IN ([@B42]). However, the role of INI1 during virus replication is still a matter of debate. Co-transfection of the minimal IN-binding domain of INI1, including the Rpt1 region, with HIV-1 proviral DNA in HEK293 cells resulted in a nearly 10,000-fold reduction in virus production from the transfected cells ([@B104]). Furthermore, subsequent studies showed that INI1 is specifically incorporated into HIV-1 virions during virus production ([@B105]), suggesting a possible role of INI1 in the late stage of HIV-1 replication rather than in the integration step. Interestingly, it was revealed that IN and INI1 selectively recruit the components of the Sin3a--HDAC1 complex into HIV-1 virions, whereafter it is required for the reverse transcription step following the infection of subsequent target cells ([@B78]). Thus, INI1 does not seem to be involved in the integration step in spite of its interaction with IN.

Lens epithelium-derived growth factor (LEDGF) is the first cellular protein to have been demonstrated as a *bona fide* cofactor for HIV-1 integration ([@B26]). LEDGF is a transcriptional regulatory protein with a molecular mass of 76 kDa from the hepatoma-derived growth factor (HDGF)-related protein (HRP) family, and was found to be strongly associated with chromatin throughout the cell cycle. This protein was identified as an interaction partner of HIV-1 IN through a co-immunoprecipitation study in human cells ([@B14]) and has been shown to stimulate *in vitro* integration activity of IN ([@B13]). LEDGF comprises several functional domains that have been implicated in the integration process. The N-terminal of LEDGF contains the PWWP (proline--tryptophan--tryptophan--proline) domain that is highly conserved amongst the members of the HRP family and was revealed to be crucial for protein--protein interaction and/or DNA-binding. Furthermore, the N-terminal also contains a putative nuclear localization signal (NLS) and dual copies of the AT-hook DNA-binding motif ([@B26]). In addition, a limited proteolysis analysis of recombinant LEDGF has shown that an evolutionally conserved domain, termed the integrase-binding domain (IBD), is included in its C-terminal and as its name suggests, this domain was found to be crucial for the specificity of the interaction with HIV-1 IN ([@B26]).

LEDGF is likely to play a critical but not strictly essential role in HIV-1 integration and replication. A study performed using intensified RNA interference demonstrated a significant reduction of HIV-1 replication in human CD4^+^ T cells in which there was a complete knockdown of endogenous LEDGF ([@B54]). Moreover, a knockout study done in mouse embryonic fibroblasts (MEFs) cell lines reported a reduction of 90% in HIV-1 infectivity upon the depletion of LEDGF/p75 and that this reduction was ablated upon re-expression of LEDGF ([@B76]). In these studies, it was found that the block in HIV-1 infection occurs specifically at the integration step, and that both the PWWP and IBD domains are of critical importance for HIV-1 integration and replication ([@B54]; [@B76]). Based on these observations, a simple mechanism model is proposed for LEDGF's function in HIV-1 integration: LEDGF serves as a molecular adaptor that tethers HIV-1 IN to the target DNA (i.e., chromatin). Since LEDGF is a transcriptional coactivator, this tethering activity is thought to be responsible for targeting the integration site of HIV-1 into transcriptionally active regions ([@B26]).

After the PIC is formed in cytoplasm, it needs to be shuttled into the nucleus to allow the integration process to take place. One of the striking features of HIV-1 is its ability to get across the intact nuclear envelope easily even in non-dividing cells. This phenomenon is believed to be strongly associated with the karyophilic properties of the HIV-1 PIC ([@B84]). Although the main component causing the PICs to be actively imported into the nucleus remains undetermined, some host-encoded proteins that interact with IN have been reported to facilitate the nuclear import of HIV-1 PICs. To date, importin 7 and TNPO3, have been reported as IN-interacting importins that direct the HIV-1 PICs to the nucleus ([@B31]; [@B3]; [@B16]). Both proteins are members of the importin β family, which act as import receptors for cargo molecules through association with nucleoporin (NUP) of the nuclear pore complex ([@B84]). While a confocal microscopy analysis of digitonin-permeabilized human cells showed the involvement of importin 7 in the nuclear accumulation of HIV-1 integration complexes, the functional role of this protein in virus replication is still unresolved ([@B31]; [@B106]). TNPO3, an HIV-1 IN-binding protein identified by yeast two-hybrid screening, was found to promote viral nuclear import as well ([@B16]). Although subsequent studies have confirmed the requirement of TNPO3 for efficient replication of HIV-1, the TNPO3--CA interaction, rather than the TNPO3--IN interaction, is likely to be required for the nuclear import of PIC in infected cells ([@B45]; [@B22]). By the same token, another cellular protein regulating nucleocytoplasmic trafficking, NUP153, was also shown to interact with HIV-1 IN by a pull-down assay ([@B101]), but again, viral CA appears to be the viral determinant for the NUP153-mediated nuclear entry of the PIC ([@B60]).

Intriguingly, a certain host protein called Gemin2 may be of importance to the reverse transcription process of HIV-1 via its physical association with IN. Gemin2 is a component of the survival of motor neurons (SMN) complex that is essential for the biogenesis of spliceosomal small nuclear ribonucleoproteins (snRNPs) and was identified as a novel interactor of HIV-1 IN by a yeast two-hybrid screening ([@B39]). Although this cellular protein is found in the HIV-1 PIC, depletion of endogenous Gemin2 by siRNA in HIV-1-infected primary monocyte-derived macrophages resulted in impairment of the early reverse transcription step rather than the integration step ([@B39]). Furthermore, a recent study showed that viral DNA synthesis by HIV-1 RT *in vitro* is enhanced by the concerted action of Gemin2 and IN ([@B64]). This augmentation of RT activity by an IN interaction appears to be reasonable because functional interaction between HIV-1 RT and IN has been revealed ([@B95]). Hence, it would be assumed that Gemin2 serves as cofactor that stimulates and/or stabilizes the formation of the reverse transcription complex to initiate DNA synthesis through its interaction with IN ([@B59]).

Several cellular proteins have been also identified as components of HIV-1 and Moloney murine leukemia virus (MoMLV) PIC by the *in vitro* reconstitution analysis and immunoprecipitation assays of PICs isolated from virus-infected cells. These include HMG proteins, barrier-to-autointegration factor (BAF, discussed below), Ku, and LEM proteins (**Figure [2](#F2){ref-type="fig"}**). Although there are some controversies as to whether these PIC-associated factors are indispensable to retrovirus infection, they may be indirectly involved in the integration process by stabilizing the nucleoprotein complex, promoting the nuclear retention of the PIC, or protecting host cells from viral DNA termini-induced apoptosis ([@B88]; [@B90]; [@B84]). Besides the host proteins listed above, more extensive discussions about the other cellular factors interacting with the IN/PIC and their roles in retrovirus replication are presented in previous comprehensive reviews ([@B88]; [@B2]; [@B35]; [@B82]).

POTENTIAL CELLULAR INHIBITORS AGAINST INTEGRATION
=================================================

In addition to the cellular enhancers for retroviral integration, the existence of potential antiviral proteins controlling the integration activity of IN and PIC has been revealed by several recent studies. Understanding the molecular details by which these factors hamper the integration reaction may potentially lead to future therapeutic inventions against retroviral infectious diseases. Recent findings on the potential restriction factors for integration process are summarized in this section, and their molecular inhibitory mechanisms are discussed.

RAD51
=====

Although retroviral integration is completed by the gap repair step, which is believed to be mediated by the cellular DNA repair enzymes ([@B21]; [@B49]), one of the homologous recombination (HR) proteins, RAD51, has been shown to suppress HIV-1 integration ([@B23]; [@B18]). The downregulation of integration by RAD51 was first observed in a unique integration assay using a budding yeast strain in which DNA substrates containing zeocin-resistance gene flanked by HIV-1 U3 and U5 LTR ends can be integrated into genomic DNA by HIV-1 IN expressed by the yeast ([@B23]). When a haploid yeast strain deficient for the RAD51 encoding gene was examined using the integration assay, higher numbers of zeocin-resistant clones were obtained, indicating an increase in integration events in the yeast cells lacking RAD51. This result suggests that RAD51 negatively regulates the HIV-1 IN-catalyzed integration reaction in yeast. In accordance with the yeast integration assay, additional *in vitro* analyses using purified recombinant proteins showed that human RAD51 (hRAD51) inhibited integration by IN. Interestingly, HIV-1 IN binds hRAD51 *in vitro*, suggesting that the inhibition of the integration reaction may be mediated through the physical interaction between IN and RAD51 ([@B23]).

Human RAD51 belongs to the RAD52 epistasis group, and members of the RAD52 epistasis group are highly conserved in yeast and humans, which mediate mitotic HR events as well as chromosome segregation during meiosis ([@B72]). RAD51 is also an ortholog of the *E. coli* RecA (**Figure [3A](#F3){ref-type="fig"}**). The RecA family proteins possess a conserved, \~230 amino acid core domain that is involved in the binding and hydrolysis of ATP through Walker A and B motifs, with the human RAD51 also bearing a long N-terminal and a short CTDs (**Figure [3A](#F3){ref-type="fig"}**; [@B52]; [@B92]). The RAD51 protein exists as a homo-oligomer in solution, and binds to single-stranded (or double-stranded) DNA to form a right-handed helical presynaptic nucleoprotein. In the presence of ATP, RAD51 can polymerize on the DNA to form a nucleofilament that expands for thousands of bases (or base pairs, **Figure [3B](#F3){ref-type="fig"}**). This nucleoprotein filament serves as the catalytic center for DNA strand-exchange reactions during HR ([@B72]).

![**RAD51-mediated inhibition of HIV-1 integration.** **(A)** Domain structure of human RAD51. RAD51 and its bacterial counterpart, RecA, share a highly conserved \~ 230 amino acid domain that contains two putative ATP-binding domains, Walker A and Walker B motifs. DNA-binding activity of hRAD51 is attributed to its N-terminal domain, which includes a modified HhH motif, while RecA binds to DNA through its long C-terminal domain. **(B)** Nucleofilament formation of RAD51. Upon assembly on DNA, RAD51 forms a right-handed helical polymer on the DNA in presence of ATP, and the RAD51-DNA nucleoprotein filament expands to thousands of bases. **(C)** Disruption of HIV-1 integration complex by the hRAD51 nucleofilament. It is suggested that formation of an active nuclear filament following polymerization of hRAD51 on viral DNA eventually displaces IN, thereby inducing dysfunction of the HIV-1 integration complex prior to the integration reaction. Recruitment of hRAD51 onto viral DNA may be facilitated by its interaction with IN.](fmicb-03-00227-g003){#F3}

The formation of the nucleofilament is also likely to be important for the downregulation of HIV-1 IN activity by RAD51. In a recent report, [@B18] set up an*in vitro* integration assay for IN in which active nucleofilament formation of RAD51 on substrate DNA was allowed to take place. They revealed that strong inhibition of HIV-1 IN activity was only observed with wild-type hRAD51 in the presence of ATP, but not in the reactions without ATP or with an hRAD51 mutant containing a single amino acid substitution in the Walker A motif (K133A) that ablated hRAD51--ATP-binding and therefore prevented hRAD51 polymerization ([@B18]). An additional *in vitro* experiment using a substrate DNA containing LTR sequences complexed with HIV-1 IN showed that even after the IN--viral DNA complexes were formed, subsequent incubation with hRAD51-induced dissociation of IN from its substrate viral DNA. The dissociation effect was not observed with hRAD51 in the absence of ATP or with the K133A mutant ([@B18]). Given that RAD51 can polymerize on DNA in an ATP-dependent manner, these observations suggest that the formation of the nucleofilament on viral DNA is responsible for the RAD51-induced restriction of HIV-1 integration via displacement of IN (**Figure [3C](#F3){ref-type="fig"}**). Furthermore, when an allosteric effector of RAD51, RS-1 (RAD51-stimulatory compound 1), which promotes formation of the active RAD51 nucleofilament, was used, HIV-1 integration and replication was significantly impaired in CD4^+^ cells. This was accompanied in an increase in 2-LTR circles, which is a byproduct from the failure to integrate ([@B18]). This *in vivo* experiment supports the proposed model in which hRAD51 recruited by HIV-1 IN is able to release the IN from viral DNA via formation of the nucleofilament, resulting in dysfunction of the PIC (**Figure [3C](#F3){ref-type="fig"}**). Although it is still unclear whether the hRAD51 in a natural setting could restrict HIV-1 integration, this study provides the possibility of using a specific stimulator of RAD51 such as RS-1 for a new antiviral approach against HIV infection.

KAP1
====

Posttranslational modifications (PTMs) including phosphorylation, ubiquitination, and acetylation is the chemical alternation of a protein's primary structure after its translation, a process which is well known to have a great impact on various protein functions such as enzymatic activity, protein--protein interaction, and subcellular localization ([@B91]). Although the association between PTMs and the retroviral integration process has not been fully addressed, it was demonstrated that the enzymatic activity of HIV-1 IN is positively regulated by histone acetyl transferases (HATs; [@B12]; [@B87]). HATs are the cellular enzymes that transfer an acetyl group from acetyl-coenzyme A (acetyl-CoA) to the ε-amino group of certain basic lysine residues of histone's N-terminal, which modifies the accessibility of DNA to other proteins ([@B69]). p300, the first HAT protein that was reported to catalyze the acetylation of HIV-1 IN, is a \~300 kDa nuclear phosphoprotein originally isolated as an interaction partner of adenovirus E1A ([@B79]). This HAT is also a paralog of the CREB-binding protein (CBP), and the p300/CBP family proteins contain several identical domains necessary for their function as HATs, which include three cysteine--histidine rich domains (CH1, CH2, CH3), a KIX domain, a bromodomain, and a HAT domain. (**Figure [4A](#F4){ref-type="fig"}**). p300 directly binds to and acetylates three specific lysine residues, Lys-264, Lys-266, and Lys-273, of the C-terminal region of HIV-1 IN (**Figure [4C](#F4){ref-type="fig"}**), which is likely to enhance the binding affinity to LTR DNA as well as strand transfer activity of IN *in vitro* ([@B12]). Importantly, an HIV-1 strain that contained arginine substitutions at the critical C-terminal lysine residues on IN exhibited a significant replication defect in CD4^+^ cells, and the replication defect occurred at the integration step, indicating the importance of C-terminal acetylation of IN in HIV-1 integration ([@B12]). An another HAT, GCN5 (**Figure [4A](#F4){ref-type="fig"}**), was also found to mediate the acetylation of HIV-1 IN at the same C-terminal lysines, and HIV-1 integration was shown to be impaired in GCN5 knockdown cells ([@B87]).

![**Regulation of HIV-1 integration by acetylation and deacetylation of IN.** **(A)** Acetyltransferases for HIV-1 IN. p300 and GCN5 have been identified as cellular enzymes catalyzing acetylation of HIV-1 IN. Both proteins are members of histone acetyltransferase (HAT) family, which transfer an acetyl group from acetyl coenzyme A to specific lysine residues on substrate proteins; HATs function as transcriptional co-activators in the nucleus. Although a conserved HAT domain is indispensable to acetylation activity of HATs, other domains including bromodomain (Br) apparently have effects on their function. p300 is able to bind a variety of transcription factors through cysteine-histidine-rich module (CH1, CH2, and CH3) and KIX domain. Nr, nuclear receptor-interacting box; PCAF-HD, PCAF homology domain. **(B)** Schematic of KAP1. KAP1, also known as TRIM28, is highly related to three other TRIM proteins, TIF1α, TIF1γ, and TIF1δ. The TIF proteins, including KAP1, exhibit similar domain organization, which includes RBCC (Ring/B-box/coiled coil) domain at the N-terminal, TIF1 signature sequence (TSS) and heterochromatin protein 1 (HP1)-binding domains at central portion, and plant homeodomain (PHD) and bromodomain (Br) at C-terminal. **(C)** Restriction of HIV-1 integration by KAP1. Cellular acetyltransferase (HAT) such as p300 interacts with HIV-1 IN and catalyzes acetylation of the IN. Three lysine residues in CTD of IN (Lys-264, Lys-266, and Lys-273) have been reported as target sites for p300 and GCN5. The acetylation appears to enhance the DNA-binding activity and strand transfer activity of IN. In a proposed model, KAP1 specifically recognizes the acetylated form of IN and induces a protein complex formation with histone deacetylase (HDAC), resulting in deacetylation of IN and reduced integration activity.](fmicb-03-00227-g004){#F4}

In the case of histones, acetylation of the internal lysines affects several aspects of nucleosome function and generates new protein--protein interactions. However, it is a reversible process, and transcriptional activation of the nucleosome is repressed by deacetylation mechanisms, which are mediated by histone deacetylases (HDAC; [@B74]). It is likely that deacetylation of HIV-1 IN also takes place. To find a cellular partner that selectively recognizes the acetylated IN, Cereset and colleagues developed a unique yeast two-hybrid screening assay, in which acetylated HIV-1 IN was constitutively expressed as the bait by fusion of the p300 HAT domain to IN ([@B1]). From the screening of a human lymphocyte cDNA library, they identified that a cellular protein, KAP1 was able to interact with acetylated IN (**Figure [4B](#F4){ref-type="fig"}**; [@B1]). KAP1 was first identified as a transcriptional corepressor that is recruited to its target genes via interaction with the Kruppel-associated box-domain-containing (KRAB) zinc-finger DNA proteins ([@B32]; [@B65]). Interestingly, KAP1 is a member of the human TRIM family, and hence contains a RBCC (Ring \[really interesting new gene\] finger, two B-box zinc fingers and a coiled coil) domain at the N-terminal, which is a characteristic feature of the TRIM family protein domains (**Figure [4B](#F4){ref-type="fig"}**; [@B40]). Additionally, KAP1, also called TRIM28 and transcription intermediary factor (TIF) 1β, is composed of a plant homeodomain (PHD) and bromodomain at the C-terminus, and contains a central TIF1 signature sequence (TSS) domain and a heterochromatin protein 1 (HP1)-binding domain, which are found in other TIF1 subfamily members ([@B40]). In accordance with the yeast two-hybrid screen, preferential binding of KAP1 to acetylated HIV-1 IN was confirmed by *in vitro* and *in vivo* analysis. Importantly, knockdown of KAP1 increased the level of integration in HIV-1-infected cells, which was accompanied by a decrease in 2-LTR circles ([@B1]). When the infection experiments were performed with HIV-1 carrying mutations in the C-terminal lysines (Lys-264, Lys-266, Lys-273) of IN, knockdown of KAP1 did not significantly increase the levels of integrated DNA, indicating that KAP1-mediated inhibition was related to the C-terminal acetylation of IN. Consistent with this, the level of acetylated IN was shown to be decreased by expression of KAP1 in cells ([@B1]). KAP1 has been reported to form complexes with HDAC to regulate transcription at specific target sites on the genome via modification of histone structure ([@B40]). Together with the observation that KAP1 has a higher affinity to acetylated IN, the evidence raises a possibility that KAP1 may serve as a scaffolding mediator that recruits HDAC to acetylated HIV-1 IN (**Figure [4C](#F4){ref-type="fig"}**). Indeed, HIV-1 IN formed a complex with KAP1 and HDAC1, and HIV-1 integration was enhanced by treatment with the HDAC inhibitors ([@B1]). These evidences therefore support the proposed model that KAP1 recruits the HDAC to acetylated IN allowing for the HDAC1-mediated deacetylation of IN to take place, which results in the subsequent reduction of integration efficiency in HIV-1 infection (**Figure [4C](#F4){ref-type="fig"}**).

A different inhibitory mechanism of KAP1 has been also demonstrated in other retroviruses and endogenous retroviruses, which involves the transcriptional repression of the provirus in embryonic carcinoma and embryonic stem cells ([@B97], [@B99]; [@B100]; [@B61]; [@B70]). The KAP1-mediated inhibition of viral transcription appeared to be largely attributable to the recruitment of KAP1 to certain types of primer binding sites (PBS) near the 5′ end of the provirus containing PBS sequences complementary to tRNA^Pro^ (MoMLV and human T-lymphotropic virus type I \[HTLV-1\]) and tRNA^Lys-1,2^ (spumavirus and Mason--Pfeizer monkey virus; [@B100]; [@B99]). In contrast, HIV-1 is not susceptible to the transcriptional silencing induced by KAP1 as its PBS is complementary to neither tRNA^Pro^ nor tRNA^Lys-1,2^ ([@B100]). Since the study by Cereset and colleagues showed that MoMLV integration was not affected by depletion of KAP1 ([@B1]), the KAP1-mediated retroviral integration block should only occur in HIV-1 replication due to the specific interaction between KAP1 and HIV-1 IN. Therefore, it can be concluded that KAP1 is an intrinsic restriction factor against a broad range of retroviruses, which inhibits either the integration or post-integration step. However, despite the ubiquitous expression of KAP1 in many cell types, substantial levels of HIV-1 integration can still be detected, indicating KAP1 may not be a very powerful integration inhibitor. Yet, it would shed light on a potentially novel KAP1-based strategy for the treatment of retrovirus infections.

REGULATION OF INTEGRASE STABILITY BY PHOSPHORYLATION: IMPLICATION OF UNKNOWN CELLULAR INHIBITORY FACTOR INVOLVED IN DEGRADATION OF UNPHOSPHORYLATED INTEGRASE
=============================================================================================================================================================

Phosphorylation is another type of PTM that is also likely to influence in HIV-1 integration. Recently, phosphorylation of HIV-1 IN by c-Jun NH~2~-terminal kinase (JNK) was reported ([@B57]). JNK is one of the major groups of mitogen-activated protein kinases (MAPKs), a family of well-studied serine/threonine kinases involved in signal transduction from extracellular stimuli such as growth factors, cytokines, infection, and stress ([@B68]; [@B11]). JNK consists of three variants, JNK1, JNK2, and JNK3, which are generated through alternative splicing but exhibit distinct expressions and functions ([@B71]). The MAPK signaling pathway can also be activated by the interaction of T cell receptors with antigen-major histocompatibility complex (MHC) class II molecules, resulting in T cell activation ([@B94]). In HIV infection, the requirement for the activation states of CD4^+^ T cells for efficient initiation and maintenance of replication has been well established ([@B81]; [@B67]; [@B80]; [@B15]). In particular, it has been demonstrated that HIV-1 infection is restricted at the post-entry stages in resting T cells, following reverse transcription and prior to integration ([@B8]; [@B66]; [@B17]).

[@B57] reported that although expression levels of JNK was low in the resting CD4^+^ T cells, it became activated upon stimulation, and that even in activated CD4^+^ T cells, HIV-1 infection was impaired by treatment with a specific JNK inhibitor, SP600125. Furthermore, decreased amounts of integrated DNA was detected in the SP600125-treated activated CD4^+^ T cells, indicating JNK contributes to the efficient infection and integration of HIV-1. Importantly, IN was found to be phosphorylated, and a conserved serine residue in the CCD, Ser-57, was identified as the target site of phosphorylation. Since the phosphorylated IN could not be detected in cells treated with SP600125, JNK appeared to be the kinase responsible for the phosphorylation of IN ([@B57]).

Next question to be asked was how the IN phosphorylation augmented the efficiency of HIV-1 integration. *In vitro* integration activity assays using recombinant IN showed that an alanine substitution at the Ser-57 residue did not affect the strand transfer activity of HIV-1 IN, suggesting that this serine residue itself is not involved in the enzymatic activity of IN ([@B57]). Meanwhile, [@B57] found that the Ser-57 and a flanking Pro-58 are conserved amongst most of the HIV-1 clades and subtypes, and that the phosphorylated of the serine/proline motif can potentially be recognized by peptidyl-prolyl *cis-trans* isomerase (PPIase), Pin1 ([@B55]). Pin1 is a regulator of phosphorylation signaling which specifically recognizes phosphorylated serine or threonine residues preceding a proline. Pin1 then catalyzes the structural rearrangement of a target molecule through *cis-trans* isomerization of its specific proline ([@B55]). Pin1 binds wild-type HIV-1 IN, but not the IN mutant with a single amino acid mutant on the phosphorylation site (S57A). As expected, treatment of IN-expressing cells with a Pin1 inhibitor, Pib, decreased the stability of HIV-1 IN. Moreover, *in vitro* incubation of recombinant IN with Pin1 increased IN resistance against a protease, subtilisin, suggesting that Pin1 induced a conformational change in phosphorylated IN, thereby rendering it less sensitive to protein degradation ([@B57]). Supporting this notion, treatment of cells with a Pin1 inhibitor or the depletion of endogenous Pin1 by siRNA reduced the level of integrated DNA in HIV-1-infected cells without any impairment of the reverse transcription step ([@B57]). More important, whereas HIV-1 carrying the S57A IN mutant exhibited decreased integration activity, treatment with the proteasome inhibitor MG132 restored integration activity ([@B57]), demonstrating that JNK-mediated phosphorylation of HIV-1 IN at Ser-57 and subsequent prolyl *cis-trans* isomerization by Pin1 increased the stability of IN and thereby enhanced integration efficiency in infected CD4^+^ T cells. Taken together, resting CD4^+^ T cells could have lower expression/activation levels of JNK, leading to decreased IN phosphorylation and consequently decreased IN stability, resulting in inefficient HIV-1 replication. Also, one could speculate that extracellular stimulations, including cytokines and chemokines, may enhance integration in resting T cells via activation of the JNK pathway ([@B10]; [@B38]).

Of particular interest is that the study by [@B57] also implies yet-to-be identified host factor(s) participating the degradation of IN, particularly unphosphorylated form of IN, in the resting T cells. HIV-1 IN is well known to undergo proteasome-mediated degradation via ubiquitination ([@B24]). A previous study has reported that the von Hippel--Lindau binding protein 1 (VBP1) and cullin2-based von Hippel--Lindau (Cul2/VHL) ubiquitin ligase cooperate to mediate the polyubiquitination and subsequent proteasomal degradation of IN, but this event was likely to occur at a post-integration step and also to promote gene expression from the integrated provirus in the nucleus ([@B62]). Therefore, further work will be required to identify novel ubiquitin--proteasome proteolytic pathways that drive the cytoplasmic degradation of HIV-1 IN in a manner that restricts integration.

VACCINIA-RELATED KINASES
========================

Integration reactions mediated by PICs can be categorized into two pathways: (i) intermolecular integration into a target DNA and (ii) intramolecular integration into the viral DNA, which is also called autointegration ([@B46]). In order to establish productive infection, the retrovirus (or retroviral PIC) needs to avoid the suicidal autointegration pathway. Hence, a strong preference for intermolecular integration is one of the key features of the retroviral PIC ([@B46]). BAF was identified as a host factor responsible for blocking the autointegration of MoMLV PICs ([@B47]). BAF is a small dimeric protein ([@B58]) and shown as a cellular component of HIV-1 and MoMLV PICs ([@B83]; [@B51]). Crystal structure analysis has revealed that BAF binds double-stranded DNA through its helix-hairpin-helix (HhH) motif ([@B6]; **Figure [5A](#F5){ref-type="fig"}**). Importantly, the dimerization of BAF appears to cross-bridge DNA, thereby preventing the autointegration of retroviral PICs by compacting viral DNA into rigid structure ([@B47]; [@B83]; [@B6]).

![**Disruption of the retroviral PIC by phosphorylation of BAF.** **(A)** Features of BAF. BAF is highly conserved among multicellular eukaryotes, and 86 out of 89 amino acid residues are identical between humans and mice. This protein is composed of five helices (α-1 to -5) and a 3~10~-helical turn, and DNA-binding activity of BAF is thought to be attributed to the HhH motif. N-terminal threonine (T) and serine (S) residues (Thr-2, Thu-3, and Ser-4) indicated in red are reported as phosphorylation sites of BAF. **(B)** VRK family proteins. Domain organization of mouse VRKs and their vaccinia viral homolog, B1 kinase, are shown. All the VRK/B1 family proteins contain highly conserved enzymatic domain involved in the phosphotransfer reaction, which is consists of the ATP binding motifs (Walker A and Walker B), catalytic domain (subdomain VI), active site (subdomain VII), and substrate recognition domain (subdomain VIII). However, some substitutions in several residues are found in Walker A, Walker B, and subdomain VI of VRK3, which may affect kinase activity of this ortholog. Additionally, VRK1 and VRK3 possess putative NLS at the C-terminal and N-terminal portions, respectively. **(C)** Reciprocal regulation of PIC integration activity by BAF and VRK. As the viral double-stranded DNA is synthesized by reverse transcription, BAF is recruited into the PIC in cytoplasm through direct binding with viral DNA. Once BAF is incorporated into the PIC, viral DNA is intramolecularly bridged by BAF's dimerization and DNA-binding activities. This intramolecular bridging by BAF compacts the viral DNA, making it less accessible as a target for autointegration. In addition, PIC associated BAF also anchors to the target DNA by its DNA bridging property (intermolecular bridging), thereby stimulating the intermolecular integration activity of the PIC. On the other hand, VRK is able to induce release of BAF from the PIC via phosphorylation of BAF. By the dissociation of BAF, viral DNA may adopt a more open structure, resulting in its increased availability for autointegration.](fmicb-03-00227-g005){#F5}

Barrier-to-autointegration factor is involved in the organization of nuclear architecture through interaction with lamin A and lamina-associated polypeptide 2-emerin-MAN1 (LEM) family proteins, and therefore predominantly localizes in the nucleus during interphase ([@B58]). On the other hand, in the mitotic phase, BAF is diffusely localized and subsequently assembles on the chromatin core region at anaphase to form a scaffold for the gathering of lamin A and LEM proteins to reconstitute the nuclear envelope ([@B73]; [@B58]). Intriguingly, these cell cycle-dependent actions of BAF appear to be regulated by the phosphorylation ([@B58]). So far, vaccinia-related kinases (VRKs) have been identified as the cellular kinases that participate in the BAF phosphorylation (**Figure [5B](#F5){ref-type="fig"}**; [@B63]). VRKs are a family of serine/threonine kinases, and three alternative splicing isoforms, VRK1, VRK2, and VRK3, are found in human and murine cells ([@B63]; [@B44]). They share several domains comprised of ATP-binding motifs (Walker A and Walker B), catalytic domains (subdomain VI), active sites (subdomain VII), and substrate recognition domains (subdomain VIII; **Figure [5B](#F5){ref-type="fig"}**; [@B5]). VRK was first identified as cellular homolog of the poxvirus (vaccinia virus) B1 kinase that plays an essential role in viral DNA replication in the early stage of vaccinia virus infections (**Figure [5B](#F5){ref-type="fig"}**; [@B63]). Importantly, VRK-mediated phosphorylation of BAF causes the loss of its DNA-binding ability ([@B63]). Depletion of VRK1 in *Caenorhabditis elegans* results in several mitotic defects and BAF delocalization ([@B36]), suggesting that the release of BAF from chromatin during mitosis is regulated by the VRK family proteins in a phosphorylation-dependent manner.

Since the DNA-binding property of BAF is crucial to the authentic integration activity of the retroviral PIC, down-modulation of the BAF activity by phosphorylation may disrupt the integration function of the PIC through dissociation of BAF from viral DNA. Indeed, our recent study revealed that BAF could be removed from the PIC following treatment with recombinant VRK1 *in vitro*([@B85]). More important, the intermolecular integration activity of the PIC assay was strongly inhibited by the VRK1 treatment, and this was accompanied by an increase in autointegration activity ([@B46]; [@B85]). Little inhibition of the PIC activity was observed in following treatment with mutant VRK1 harboring alanine substitutions in the catalytic subdomain VI, and also in PICs treated with wild-type VRK1 in the presence of a well-known kinase inhibitor, staurosporine, indicating that disruption of PIC function is attributed to the kinase activity of VRK1 ([@B85]). Based on these findings, a potential inhibitory mechanism by which VRK1 restricts PIC integration activity can be proposed: phosphorylation by VRK1 dissociates BAF from the PIC, resulting in destructive autointegration of viral DNA (**Figure [5C](#F5){ref-type="fig"}**).

When other members of the VRK family of proteins were assessed for their ability to inhibit the intermolecular integration activity of PICs, VRK2, but not VRK3, was found to abrogate the function of PICs in a similar manner with VRK1 ([@B85]). This raised the question of why VRK3 was unable to inhibit PIC activity. Phosphorylation of BAF exhibits biphasic phases (hypophosphorylation and hyperphosphorylation), with the phosphorylation taking place on the Thr-2, Thr-3, and Ser-4 located on the N-terminus of BAF (**Figure [5A](#F5){ref-type="fig"}**). VRK1 and VRK2 are able to catalyze the hyperphosphorylation ([@B63]). However, the BAF product phosphorylated by VRK3 is the hypophosphorylated form, and an *in vitro* kinase assay using BAF mutants, in which Thr-2, Thr-3, and/or Ser-4 had been substituted with alanine, revealed that Ser-4 is the sole site for the VRK3-mediated hypophosphorylation ([@B85]). Ser-4 has been also indicated as initial phosphorylation site by VRK1 and VRK2 ([@B63]) and our preliminary results of an *in vitro* kinase assay using BAF mutants showed that subsequent phosphorylation likely takes place on Thr-3 (Suzuki and Suzuki, unpublished data). These results suggest that Ser-4 is the primary target of all VRK family proteins, but that Thr-3 is an additional preferred target of VRK1 and VRK2. The hyperphosphorylation of BAF at both the N-terminal Thr-3 and Ser-4 should therefore be a prerequisite for the functional disruption of PIC function. Although the findings of our *in vitro* studies propose that VRK is a cellular kinase harboring potentially restrictive activity against retroviral integration, delineating the precise role of the VRK family of proteins in retrovirus infection and integration *in vivo* requires further experimentation.

CONCLUSION
==========

As discussed in this review, the processes leading up to integration are assisted by a number of host proteins. Furthermore, it has become evident that there are some cellular proteins that act as potential restriction factors. Research into intracellular effectors and inhibitors of retroviral integration therefore provides an important insight for the development of novel classes of anti-HIV drugs that can act synergistically with existing drugs targeting the active sites of viral enzymes or the binding pockets of cellular receptors.
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